1. Home
  2. LYG vs ALNY Comparison

LYG vs ALNY Comparison

Compare LYG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYG
  • ALNY
  • Stock Information
  • Founded
  • LYG 1695
  • ALNY 2002
  • Country
  • LYG United Kingdom
  • ALNY United States
  • Employees
  • LYG 62569
  • ALNY N/A
  • Industry
  • LYG Commercial Banks
  • ALNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • LYG Finance
  • ALNY Health Care
  • Exchange
  • LYG Nasdaq
  • ALNY Nasdaq
  • Market Cap
  • LYG 42.9B
  • ALNY 34.7B
  • IPO Year
  • LYG N/A
  • ALNY 2004
  • Fundamental
  • Price
  • LYG $2.84
  • ALNY $235.56
  • Analyst Decision
  • LYG Buy
  • ALNY Buy
  • Analyst Count
  • LYG 4
  • ALNY 23
  • Target Price
  • LYG $2.75
  • ALNY $295.00
  • AVG Volume (30 Days)
  • LYG 10.8M
  • ALNY 924.2K
  • Earning Date
  • LYG 10-23-2024
  • ALNY 10-31-2024
  • Dividend Yield
  • LYG 5.23%
  • ALNY N/A
  • EPS Growth
  • LYG N/A
  • ALNY N/A
  • EPS
  • LYG 0.09
  • ALNY N/A
  • Revenue
  • LYG $24,874,681,670.00
  • ALNY $2,094,795,000.00
  • Revenue This Year
  • LYG N/A
  • ALNY $25.14
  • Revenue Next Year
  • LYG $4.77
  • ALNY $17.13
  • P/E Ratio
  • LYG $7.25
  • ALNY N/A
  • Revenue Growth
  • LYG 7.75
  • ALNY 21.54
  • 52 Week Low
  • LYG $2.00
  • ALNY $141.98
  • 52 Week High
  • LYG $3.24
  • ALNY $304.39
  • Technical
  • Relative Strength Index (RSI)
  • LYG 45.08
  • ALNY 27.06
  • Support Level
  • LYG $2.71
  • ALNY $264.11
  • Resistance Level
  • LYG $2.81
  • ALNY $271.08
  • Average True Range (ATR)
  • LYG 0.05
  • ALNY 8.79
  • MACD
  • LYG -0.00
  • ALNY -3.97
  • Stochastic Oscillator
  • LYG 73.53
  • ALNY 1.28

About LYG Lloyds Banking Group Plc

Lloyds is a retail and commercial bank headquartered in the United Kingdom. The bank operates via three business segments: retail, commercial banking, and insurance and wealth. In retail, Lloyds offers primarily mortgages (66% of loan portfolio), credit cards, and current accounts to its customers. Its commercial banking operation provides lending, transaction banking, working capital management, and debt capital market services to large companies and financial institutions in the UK Insurance and wealth rounds out the product lineup with life and property insurance as well as pension solutions and high-net-worth asset-management services.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: